dopaminergic for RLS: rotigotine transdermal system (Neupro)
place in therapy: moderate/severe primary RLS
FDA approved
AE: rotigotine (Neupro)
application site reactions, nausea, somnolence, h/a
anticonvulsants for RLS: Gabapentin enacarbil (Horizant)
place in therapy: moderate to severe - adults
FIRST-LINE: painful, combo with peripheral neuropathy
FDA approved
PRODRUG to gabapentin
longer acting
better absorbed, costly, no evidence though
Gabapentin enacarbil (Horizant) administration
NOT 1:1 with regular gabapentin (100-300 mg) so no sub
oral 600 mg QD (no increase needed)
RENALLY ADJUSTED
AE: gabapentin enacarbil (Horizant)
somnolence, dizziness
watch out for elderly, renal impairment
benzodiazepines for RLS:
place in therapy: alt tx to levodopa with mild-intermittent sx, add on in severe, poor sleep
mixed results
improve sleep
clonazepam 0.5-2 mg (long half-life)
administration: oral before bedtime
AE: benzodiazepines
sedation, daytime somnolence
opioids for RLS: tramadol, propoxyphene, hydrocodone, oxycodone, codeine, methadone
place in therapy: painful/refractory RLS, relieve pain, motor restlessness, sleep disturbances
administration: prior to bedtime
QD - TID on timing of sx
AE: opioids
respiratory depression, sedation, constipation
Author
VASUpharm14
ID
211535
Card Set
Restless Legs Syndrome - Lecture 5 - Dr. Scopelliti
Description
M/S RLS
Define the signs and symptoms of restless legs syndrome (RLS)
Understand the pathophysiology of RLS
Identify associated conditions related to the etiology of RLS
List the essential diagnostic criteria for RLS
Evaluate the pharmacological treatment options for RLS
Develop an appropriate treatment plan for a patient with RLS